Menopause after breast cancer: A survey on breast cancer survivors

Nicoletta Biglia, Marilena Cozzarella, Franca Cacciari, Riccardo Ponzone, Riccardo Roagna, Furio Maggiorotto, Piero Sismondi

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Due to the younger age and the ever wider use of adjuvant chemotherapy and antiestrogens, menopausal symptoms are a frequent cause of concern for breast cancer patients. Objectives: To determine the prevalence of menopausal symptoms, and to explore the attitudes toward Hormone Replacement Therapy (HRT) or other treatments and the willingness to take oestrogen in breast cancer patients. Methods: A questionnaire-based survey on 250 breast cancer patients treated and followed-up at our department. Of them 144 (Group A) were in postmenopause and 106 (Group B) were in premenopause at time of diagnosis. Results: Adjuvant therapy with tamoxifen or tamoxifen plus chemotherapy is associated with a significant worsening of menopause-related symptoms of women belonging to Group A. These women are more concerned about risk of breast cancer recurrence than about risk of osteoporosis (P=0.05) and heart disease (P=0.006). Seventy-eight percent are against the use of HRT; only 22% would consider taking HRT mainly for vasomotor symptoms relief and osteoporosis prevention. The incidence of vasomotor and dystrophic symptoms is significantly higher in women belonging to Group B treated with chemotherapy and/or hormonotherapy as compared with postmenopausal women (P

Original languageEnglish
Pages (from-to)29-38
Number of pages10
JournalMaturitas
Volume45
Issue number1
DOIs
Publication statusPublished - May 30 2003

Fingerprint

Chemotherapy
Menopause
Survivors
Hormone Replacement Therapy
Hormones
Tamoxifen
Breast Neoplasms
Osteoporosis
Estrogen Receptor Modulators
Premenopause
Postmenopause
Drug Therapy
Estrogens
Adjuvant Chemotherapy
Heart Diseases
Recurrence
Surveys and Questionnaires
Incidence
Therapeutics

Keywords

  • Adjuvant therapy
  • Breast cancer
  • Hormone replacement therapy

ASJC Scopus subject areas

  • Ageing
  • Obstetrics and Gynaecology

Cite this

Menopause after breast cancer : A survey on breast cancer survivors. / Biglia, Nicoletta; Cozzarella, Marilena; Cacciari, Franca; Ponzone, Riccardo; Roagna, Riccardo; Maggiorotto, Furio; Sismondi, Piero.

In: Maturitas, Vol. 45, No. 1, 30.05.2003, p. 29-38.

Research output: Contribution to journalArticle

Biglia, N, Cozzarella, M, Cacciari, F, Ponzone, R, Roagna, R, Maggiorotto, F & Sismondi, P 2003, 'Menopause after breast cancer: A survey on breast cancer survivors', Maturitas, vol. 45, no. 1, pp. 29-38. https://doi.org/10.1016/S0378-5122(03)00087-2
Biglia, Nicoletta ; Cozzarella, Marilena ; Cacciari, Franca ; Ponzone, Riccardo ; Roagna, Riccardo ; Maggiorotto, Furio ; Sismondi, Piero. / Menopause after breast cancer : A survey on breast cancer survivors. In: Maturitas. 2003 ; Vol. 45, No. 1. pp. 29-38.
@article{b93e174a52a34c858438adeb0d754840,
title = "Menopause after breast cancer: A survey on breast cancer survivors",
abstract = "Due to the younger age and the ever wider use of adjuvant chemotherapy and antiestrogens, menopausal symptoms are a frequent cause of concern for breast cancer patients. Objectives: To determine the prevalence of menopausal symptoms, and to explore the attitudes toward Hormone Replacement Therapy (HRT) or other treatments and the willingness to take oestrogen in breast cancer patients. Methods: A questionnaire-based survey on 250 breast cancer patients treated and followed-up at our department. Of them 144 (Group A) were in postmenopause and 106 (Group B) were in premenopause at time of diagnosis. Results: Adjuvant therapy with tamoxifen or tamoxifen plus chemotherapy is associated with a significant worsening of menopause-related symptoms of women belonging to Group A. These women are more concerned about risk of breast cancer recurrence than about risk of osteoporosis (P=0.05) and heart disease (P=0.006). Seventy-eight percent are against the use of HRT; only 22{\%} would consider taking HRT mainly for vasomotor symptoms relief and osteoporosis prevention. The incidence of vasomotor and dystrophic symptoms is significantly higher in women belonging to Group B treated with chemotherapy and/or hormonotherapy as compared with postmenopausal women (P",
keywords = "Adjuvant therapy, Breast cancer, Hormone replacement therapy",
author = "Nicoletta Biglia and Marilena Cozzarella and Franca Cacciari and Riccardo Ponzone and Riccardo Roagna and Furio Maggiorotto and Piero Sismondi",
year = "2003",
month = "5",
day = "30",
doi = "10.1016/S0378-5122(03)00087-2",
language = "English",
volume = "45",
pages = "29--38",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Menopause after breast cancer

T2 - A survey on breast cancer survivors

AU - Biglia, Nicoletta

AU - Cozzarella, Marilena

AU - Cacciari, Franca

AU - Ponzone, Riccardo

AU - Roagna, Riccardo

AU - Maggiorotto, Furio

AU - Sismondi, Piero

PY - 2003/5/30

Y1 - 2003/5/30

N2 - Due to the younger age and the ever wider use of adjuvant chemotherapy and antiestrogens, menopausal symptoms are a frequent cause of concern for breast cancer patients. Objectives: To determine the prevalence of menopausal symptoms, and to explore the attitudes toward Hormone Replacement Therapy (HRT) or other treatments and the willingness to take oestrogen in breast cancer patients. Methods: A questionnaire-based survey on 250 breast cancer patients treated and followed-up at our department. Of them 144 (Group A) were in postmenopause and 106 (Group B) were in premenopause at time of diagnosis. Results: Adjuvant therapy with tamoxifen or tamoxifen plus chemotherapy is associated with a significant worsening of menopause-related symptoms of women belonging to Group A. These women are more concerned about risk of breast cancer recurrence than about risk of osteoporosis (P=0.05) and heart disease (P=0.006). Seventy-eight percent are against the use of HRT; only 22% would consider taking HRT mainly for vasomotor symptoms relief and osteoporosis prevention. The incidence of vasomotor and dystrophic symptoms is significantly higher in women belonging to Group B treated with chemotherapy and/or hormonotherapy as compared with postmenopausal women (P

AB - Due to the younger age and the ever wider use of adjuvant chemotherapy and antiestrogens, menopausal symptoms are a frequent cause of concern for breast cancer patients. Objectives: To determine the prevalence of menopausal symptoms, and to explore the attitudes toward Hormone Replacement Therapy (HRT) or other treatments and the willingness to take oestrogen in breast cancer patients. Methods: A questionnaire-based survey on 250 breast cancer patients treated and followed-up at our department. Of them 144 (Group A) were in postmenopause and 106 (Group B) were in premenopause at time of diagnosis. Results: Adjuvant therapy with tamoxifen or tamoxifen plus chemotherapy is associated with a significant worsening of menopause-related symptoms of women belonging to Group A. These women are more concerned about risk of breast cancer recurrence than about risk of osteoporosis (P=0.05) and heart disease (P=0.006). Seventy-eight percent are against the use of HRT; only 22% would consider taking HRT mainly for vasomotor symptoms relief and osteoporosis prevention. The incidence of vasomotor and dystrophic symptoms is significantly higher in women belonging to Group B treated with chemotherapy and/or hormonotherapy as compared with postmenopausal women (P

KW - Adjuvant therapy

KW - Breast cancer

KW - Hormone replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=0037837382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037837382&partnerID=8YFLogxK

U2 - 10.1016/S0378-5122(03)00087-2

DO - 10.1016/S0378-5122(03)00087-2

M3 - Article

C2 - 12753941

AN - SCOPUS:0037837382

VL - 45

SP - 29

EP - 38

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - 1

ER -